PDCD1 and cancer: Following immune checkpoint inhibitors targeting programmed cell death protein 1 and its ligand 1, the mRNA-cancer vaccine has become increasingly attractive to scientists and oncologists and could be a hotspot in cancer immunotherapy [7, 8].